JUBILANT PHARMOVA LIMITED — Call Transcript 2019

Oct 17, 2019

==> picture [172 x 133] intentionally omitted <==

October 17, 2019

BSE Limited

P. J. Towers Dalal Street, Fort Mumbai - 400 001

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E), Mumbai - 400 051

Dear Sirs,

Sub.: Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Unaudited Financial Results for the quarter ended September 30, 2019

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on October 25, 2019 after submission of the financial results for the quarter ended September 30, 2019 to the Stock Exchanges. Details of the Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully, For Jubilant Life Sciences Limited RAJIV Digitally signed by RAJIV SHAH Date: 2019.10.17 SHAH 14:44:07 +05'30' Rajiv Shah Company Secretary

Encl.: as above

==> picture [556 x 122] intentionally omitted <==

==> picture [84 x 18] intentionally omitted <==

==> picture [84 x 17] intentionally omitted <==

==> picture [84 x 17] intentionally omitted <==

==> picture [84 x 17] intentionally omitted <==

Jubilant Life Sciences Limited

1A, Sector 16A, Noida 201301, India Tel. : +91 120 4361000 www.jubl.com

Noida, Thursday October 17, 2019

Conference call on Friday, October 25, 2019 at 05:00 pm IST

The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host Q2 & H1’FY20 Earnings Conference Call for analysts and investors on Friday, October 25, 2019 at 05:00 pm IST. The call will commence with a brief management discussion on the financial performance for the quarter and half year ended September 30[th] , 2019, followed by an interactive Question & Answer session.

	Conference Dial-In Numbers	Conference Dial-In Numbers
	Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
		+91-7045671221
	Local Access Number:	Available all over India.
		USA:1 866 746 2133
	Toll Free Number:	UK:0 808 101 1573 Singapore:800 101 2045
		Hong Kong:800 964 448
		To enable participants to connect to the conference call without
		having to wait for an operator, please register at the below
		mentioned link
	Pre-registration:
		You will receive dial in numbers, passcode and a pin for the concall on
		the registered email address provided by you. Kindly dial into the call on
		the Conference Call date and use the passcode & pin to connect to call.
		Available from October 25 to November 02, 2019
	Replay Facility:	Dial in No.:+91 22 7194 5757
		Playback ID: 27287#

-ENDS -

1

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Other businesses including Drug Discovery Solutions and India Branded Pharmaceuticals. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, Generics, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectibles and Non-sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions business, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 2 world class research centers in India. Jubilant Life Sciences Limited has a team of over 7,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information please contact:

Ravi Agrawal / Vineet Mayer Jubilant Life Sciences Limited Ph: +91‐120 4361002 / 1021 E‐mail: ravi.agrawal@jubl.com vineet.mayer@jubl.com

Siddharth Rangnekar / Karl Kolah CDR India Ph: +91‐22 6645 1209 / 1220 E‐mail: siddharth@cdr‐india.com karl@cdr‐india.com

Disclaimer: Statements made on the call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

2